Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International : DiviTumTKa prognostic for long-term outcome

03/11/2021 | 05:11am EDT

Biovica, active in cancer diagnostics, today announced that the results from the breast cancer study PROMIX at Karolinska University Hospital is published in the scientific journal ESMO Open. The study showed that testing for TKa levels during early treatment is prognostic for the long-term outcome of preoperative chemotherapy.

“The study at Karolinska University Hospital is yet an example of the many notable research collaborations that Biovica has, and we are pleased to see the results being published in the well-renown ESMO Open. The results support the use of DiviTum®TKa as a blood-based alternative to the tissue-based Ki67 biomarker when assessing breast tumor cell growth. Also this is yet an evidence of DiviTum®TKa’s strong prognostic capabilities,” said Anders Rylander, CEO of Biovica.

The study, PROMIX (NCT00957125) is aimed to predict response of preoperative treatment in patients with early breast cancer. DiviTum®TKa was incorporated in the study as a blood-based biomarker to predict patient outcome measured as treatment response and risk of recurrence after performing surgery to remove the tumor. The aim was further to validate the TKa biomarker against another biomarker, Ki67, known also to measure the tumor growth activity, but within a tissue-testing workflow more cumbersome than the blood-based DiviTum®TKa analysis. Samples from 125 breast cancer patients were collected pre-treatment, during therapy and at surgery.

The results demonstrate that serial measurements of TKa during the preoperative chemotherapy treatment period provides long-term prognostic information on Event Free Survival (EFS) and Overall Survival (OS). A high increase in TKa after two cycles of chemotherapy resulted in improved EFS and OS. Hence, testing for TKa levels during early treatment will predict the long-term outcome of chemotherapy provided before surgery. The study also showed a significant interaction between the prognostic value of TKa and Ki67. This supports the use of DiviTum®TKa as a blood-based alternative to the tissue-based Ki67 biomarker when assessing breast tumor cell growth.

Link to study publication: Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer - ESMO Open

© Modular Finance, source Nordic Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
09/23BIOVICA INTERNATIONAL : Notice of extra general meeting in Biovica International AB
AQ
09/20BIOVICA INTERNATIONAL AB(OM : BIOVIC B) added to S&P Global BMI Index
CI
09/15BIOVICA INTERNATIONAL : DiviTum«TKa results from SWOG study published in Clinical Cancer R..
AQ
09/15Biovica Announces DiviTum«TKa results from SWOG study published in Clinical Cancer Rese..
CI
09/14BIOVICA INTERNATIONAL : Promising DiviTumTKa results from BioItaLEE study presented at ESM..
AQ
09/13BIOVICA INTERNATIONA : Biovica International
AQ
09/13BIOVICA INTERNATIONAL : provides update on FDA application process
AQ
09/13Biovica International AB Provides Update on FDA Application Process
CI
08/31BIOVICA INTERNATIONAL : Announcement from Biovica International's annual general meeting
AQ
08/31BIOVICA INTERNATIONAL : DiviTum«TKa approaching FDA approval
AQ
More news
Financials
Sales 2022 48,6 M 5,57 M 5,57 M
Net income 2022 -32,6 M -3,73 M -3,73 M
Net cash 2022 252 M 28,9 M 28,9 M
P/E ratio 2022 -51,9x
Yield 2022 -
Capitalization 1 489 M 171 M 171 M
EV / Sales 2022 25,4x
EV / Sales 2023 8,14x
Nbr of Employees 20
Free-Float 41,9%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 52,40 SEK
Average target price 103,00 SEK
Spread / Average Target 96,6%
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors